Exclusive Summary

• Best-in-Class PK Profile: Features a global unique chemical structure (Pyrazole) with drug exposure (AUC) and Cmax significantly superior to competitors like JNJ-379 and ABI-H0731, suggesting higher potency.
• Advanced Clinical Validation: Phase 3 ongoing in China with solid Phase 2 data showing UB063 + Entecavir achieves >95% HBV DNA undetectability and significantly reduces HBV RNA, addressing Low-Level Viremia (LLV).
• Cornerstone for Functional Cure: Uniquely positioned to block cccDNA replenishment and virion generation, making it an ideal candidate for global partnerships focusing on combination therapies (e.g., with IFN) for specific or functional cures.

Asset Materials

Contact Us for Full Materials